To evaluate the therapeutic effect of surgery combined with radiotherapy in lung cancer, 385 operative cases, and 308 received combined treatment, were analyzed. The 5-year survival rate of T3 cases among pTNM-stage III cases undergoing surgery was 2.4% (1/42), while that of cases receiving combined radiotherapy was 18.9% (14/74), which showed some effectiveness. The 5 year survival rate of N2 (n3), operation only cases and combined treatment cases were 5.3% (2/38), and 8.9% (8/90), respectively. Long-term survival among cases of extensive mediastinal metastasis (# 1-9) confirmed the effect of combined therapy. Combined therapy effect was recognized in squamous cell carcinoma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence.
Nat Cancer
January 2025
Institute for Artificial Intelligence in Medicine, University Hospital Essen (AöR), Essen, Germany.
Despite advances in precision oncology, clinical decision-making still relies on limited variables and expert knowledge. To address this limitation, we combined multimodal real-world data and explainable artificial intelligence (xAI) to introduce AI-derived (AID) markers for clinical decision support. We used xAI to decode the outcome of 15,726 patients across 38 solid cancer entities based on 350 markers, including clinical records, image-derived body compositions, and mutational tumor profiles.
View Article and Find Full Text PDFPredictive value of temporal muscle thickness for prognosis in newly diagnosed IDH wild-type glioblastoma patients: evaluated for a Chinese population.
Eur Radiol
January 2025
Department of Neurointervention, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Objectives: This study aims to investigate the prognostic value of Temporal Muscle Thickness (TMT) in Chinese patients with newly diagnosed isocitrate dehydrogenase (IDH) wild-type glioblastoma.
Methods: Data were retrospectively collected from patients with isocitrate dehydrogenase wild-type genotype glioblastoma, who underwent surgical treatment and concurrent chemoradiotherapy at our center between May 2019 and May 2023. Multi-model and multivariate Cox regression were used to examine factors associated with overall and progression-free survival.
[Multimodal Treatments for Spinal Cord Glioma: Up to Date].
No Shinkei Geka
January 2025
Division of Neurosurgery, Tohoku Medical and Pharmaceutical University.
This study reviews the diagnostic criteria and treatment strategies for spinal malignant gliomas, particularly glioblastoma with -wildtype and diffuse midline gliomas with H3-K27 alteration, according to the World Health Organization 2021 classification. Surgical resection remains challenging owing to the diffuse nature of these tumors. Even with the Stupp regimen(temozolomide and radiotherapy), the prognosis remains poor, with an average survival of 12 months.
View Article and Find Full Text PDFBackground: Radio-chemotherapy remains the mainstay of glioblastoma first-line treatment after extended surgery, but the prognosis is still poor. PARP inhibitors like olaparib may improve glioblastoma outcomes. We implemented a phase 1-2a trial to assess the safety and efficacy of olaparib combined with standard radio-chemotherapy as a first-line treatment in unresected glioblastoma patients.
View Article and Find Full Text PDFConcomitant Exacerbation of Graves Orbitopathy and Double-Seronegative Myasthenia Gravis after SARS-CoV-2 Infection.
JCEM Case Rep
February 2025
First Department of Internal Medicine, Wakayama Medical University, Wakayama 641-8509, Japan.
SARS-CoV-2 infection could trigger autoimmune disease. We report a case of concomitant exacerbation of Graves orbitopathy (GO) and myasthenia gravis (MG) after SARS-CoV-2 infection. A 43-year-old woman had diplopia, proptosis, and swollen eyelids.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!